Guided Therapeutics, Inc.
GTHP · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -100% | – | -100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | -$0 | -$0 |
| % Margin | – | 67.5% | – | -200% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $1 | $0 | $0 |
| SG&A Expenses | $0 | $1 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $1 | $1 | $0 | $1 |
| Operating Income | -$0 | -$1 | -$0 | -$1 |
| % Margin | – | -652.1% | – | -53,300% |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | -$0 |
| Pre-Tax Income | -$1 | -$1 | -$0 | -$1 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$1 | -$1 | -$0 | -$1 |
| % Margin | – | -693.2% | – | -65,200% |
| EPS | -0.01 | -0.011 | -0.007 | -0.012 |
| % Growth | 8.3% | -60.3% | 44.7% | – |
| EPS Diluted | -0.01 | -0.011 | -0.007 | -0.012 |
| Weighted Avg Shares Out | 82 | 79 | 68 | 57 |
| Weighted Avg Shares Out Dil | 82 | 79 | 68 | 57 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$1 | -$1 | -$0 | -$0 |
| % Margin | – | -535.9% | – | -49,400% |